JUNO THERAPEUTICS, INC.

Profile

Company Names

JUNO THERAPEUTICS, INC.

Addresses

400 DEXTER AVENUE NORTH, SUITE 1200, SEATTLE, WA 98109

307 WESTLAKE AVENUE NORTH, SUITE 300, SEATTLE, WA 98109

Phone Numbers

2065821600
2066960703

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2013

State Incorporated:

DELAWARE

Total Amount Raised:

$1,050,178,359.00

Number of Funding Rounds:

5
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
5
2017-09-26 
$31,091,407.00 
$31,091,407.00 
$0.00 
Equity 
4
2015-06-29 
$898,495,324.00 
INDEFINITE 
INDEFINITE 
Equity 
3
2014-08-01 
$85,499,985.00 
$133,734,641.00 
$48,234,656.00 
Equity 
2
2014-04-24 
$28,423,971.00 
$97,000,000.00 
$68,576,029.00 
Equity 
1
2013-12-13 
$6,667,672.00 
$7,145,909.00 
$478,237.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
SUNIL 
 
AGARWAL 
EXECUTIVE OFFICER
JUNO THERAPEUTICS, INC.
ROBERT 
 
AZELBY 
EXECUTIVE OFFICER
JUNO THERAPEUTICS, INC.   |  ELIEM THERAPEUTICS, INC.   |  AUTOLUS THERAPEUTICS PLC
HAL 
 
BARRON 
DIRECTOR
JUNO THERAPEUTICS, INC.   |  GRAIL, INC.
HANS 
 
BISHOP 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
JUNO THERAPEUTICS, INC.   |  GRAIL, INC.   |  LYELL IMMUNOPHARMA, INC.   |  SANA BIOTECHNOLOGY, INC.   |  OPHIREX, INC.
BERNARD 
 
CASSIDY 
EXECUTIVE OFFICER
JUNO THERAPEUTICS, INC.
BERNARD 
J. 
CASSIDY 
EXECUTIVE OFFICER
JUNO THERAPEUTICS, INC.
LARRY 
 
COREY 
DIRECTOR
JUNO THERAPEUTICS, INC.
THOMAS 
 
DANIEL 
DIRECTOR
JUNO THERAPEUTICS, INC.   |  MAGENTA THERAPEUTICS, INC.   |  IMMUSANT, INC.   |  CRITICAL TELEPHONE APPLICATIONS, INC   |  VIR BIOTECHNOLOGY, INC.
ANTHONY 
 
EVNIN 
DIRECTOR
AVEO PHARMACEUTICALS INC   |  METABOLEX, INC.   |  ACCELERON PHARMA INC   |  BOSTON POWER INC   |  CONSTELLATION PHARMACEUTICALS INC   |  ALTEA THERAPEUTICS CORP   |  JUNO THERAPEUTICS, INC.
JAY 
 
FLATLEY 
DIRECTOR
HELIXIS INC   |  GENVAULT CORP   |  HELIX HOLDINGS I, LLC   |  JUNO THERAPEUTICS, INC.   |  IRIDIA, INC.   |  CELLANOME, INC.
MARK 
 
FROHLICH 
EXECUTIVE OFFICER, PROMOTER
JUNO THERAPEUTICS, INC.   |  BIOECLIPSE THERAPEUTICS, INC.   |  INDAPTA THERAPEUTICS INC.
STEVEN 
 
HARR 
EXECUTIVE OFFICER
JUNO THERAPEUTICS, INC.
RICHARD 
 
KLAUSNER 
DIRECTOR, PROMOTER
IMMUNE DESIGN CORP.   |  JUNO THERAPEUTICS, INC.   |  GRAIL, INC.   |  MINDSTRONG, INC.   |  LIFEMINE THERAPEUTICS, INC.   |  MEDICAL CREATIONS, INC.   |  LYELL IMMUNOPHARMA, INC.   |  SONOMA BIOTHERAPEUTICS, INC.
RICK 
 
KLAUSNER 
DIRECTOR, PROMOTER
3-V BIOSCIENCES, INC.   |  PATHWORK DIAGNOSTICS INC   |  JUNO THERAPEUTICS, INC.   |  FOG PHARMACEUTICALS, INC.
HYAM 
 
LEVITSKY 
EXECUTIVE OFFICER
JUNO THERAPEUTICS, INC.
ROBERT 
 
NELSEN 
DIRECTOR, PROMOTER
FORGE INC   |  RECEPTOS, INC. (F.K.A. RECEPTOR PHARMACEUTICALS INC.)   |  AGIOS PHARMACEUTICALS INC   |  KILIMANJARO ENERGY, INC.   |  NEUROGESX INC   |  KYTHERA BIOPHARMACEUTICALS INC   |  SYROS PHARMACEUTICALS, INC.   |  FATE THERAPEUTICS INC   |  CENEXYS, INC.   |  JUNO THERAPEUTICS, INC.   |  BELLEROPHON THERAPEUTICS LLC   |  FARADAY PHARMACEUTICALS, INC.   |  SAPPHIRE ENERGY, INC.   |  UNITY BIOTECHNOLOGY, INC.   |  ARIVALE INC.   |  SIENNA BIOPHARMACEUTICALS, INC.   |  GOSSAMER BIO, INC.   |  VIR BIOTECHNOLOGY, INC.   |  BEAM THERAPEUTICS INC.   |  GRAIL, INC.   |  APEX NEURO HOLDINGS, INC.   |  NUTCRACKER THERAPEUTICS, INC.   |  SANA BIOTECHNOLOGY, INC.   |  INSITRO, INC.   |  NATIONAL RESILIENCE, INC.   |  MEDICAL CREATIONS, INC.   |  NEUMORA THERAPEUTICS, INC.   |  RIPPL CARE, INC.   |  SEAPORT THERAPEUTICS, INC.
HOWARD 
 
PIEN 
DIRECTOR
BELLEROPHON THERAPEUTICS LLC   |  JUNO THERAPEUTICS, INC.   |  SAPIENCE THERAPEUTICS, INC.
MARC 
 
TESSIER-LAVIGNE 
DIRECTOR
AGIOS PHARMACEUTICALS INC   |  JUNO THERAPEUTICS, INC.   |  DENALI THERAPEUTICS INC.
RUPERT 
 
VESSEY 
DIRECTOR
SIDECAR THERAPEUTICS, INC.   |  JUNO THERAPEUTICS, INC.
MARY 
AGNES 
WILDEROTTER 
DIRECTOR
JUNO THERAPEUTICS, INC.   |  DOCUSIGN, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2017-10-05
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
$25,000,001 - $100,000,000 
Equity 
2017-09-26 
2017-06-29
D/A
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
$5,000,001 - $25,000,000 
Equity 
2015-06-29 
2016-07-06
D/A
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
$5,000,001 - $25,000,000 
Equity 
2015-06-29 
2015-07-14
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
NO REVENUES 
Equity 
2015-06-29 
2014-08-14
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-08-01 
2014-05-08
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-04-24 
2013-12-26
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-12-13 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#